What question did this study set out to answer?

To estimate the long-term economic impact of prophylaxis versus on-demand therapy for type 3 von Willebrand disease.

July 12, 2026Blood AdvancesOpen Access

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compares cost-effectiveness of prophylaxis and on-demand therapy in type 3 VWD, indicating significant savings for prophylaxis.

To estimate the long-term economic impact of prophylaxis versus on-demand therapy for type 3 von Willebrand disease.
Conducted a trial-based cost-effectiveness analysis from payer and societal perspectives.
Derived clinical inputs from Phase 3 studies and healthcare costs from published sources.
Included productivity losses during bleeding events in the societal analysis.
Wilate prophylaxis resulted in annual savings of $10,898 per individual, $53,264 for adults, and $125,712 for women.
Savings were even higher in the societal perspective, with women benefiting by $148,555 annually.
Primary cost drivers were bleeding rates and treatment expenses during on-demand therapy.

Sidonio et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial compares cost-effectiveness of prophylaxis and on-demand therapy in type 3 VWD, indicating significant savings for prophylaxis.